BioTC Oklahoma’s Post

Thanks to everyone who joined and asked questions at our seminar with N=1 Collaborative yesterday! Our Chief Technology Officer, David Butler, spoke on a panel of experts about "Control of regulatory starting material quality for oligonucleotide therapeutics". During the talk, David provided insights into the synthesis of phosphoramidites, a systematic approach to categorizing phosphoramidite impurities, and analytical techniques for purity and impurities characterization and measurement of amidites used in N=1 oligonucleotides. Did you miss it? Don't worry, you can catch up with the recording on-demand via the link below. 👇 https://loom.ly/4n4G4Kw #Oligonucleotides #PharmaEvent #CDMO

#powerofsharing 🥁Insightful resharing of CGT market updates 🙏Serving Cell and Gene therapy market is a spectacular opportunity and I’m already vitnessing the potential opportunities. 🩺No doubt, being focused on establishing co creative strategies & ecosystem puts patients safely as priority and that’s clearly one of my top 5 strategies 🧬The cell and gene therapy market in India, Southeast Asia, Taiwan, and Australia is poised for explosive growth over the next five years. 📍With innovations in personalized medicine, rising healthcare investments, and supportive regulations, this region is emerging as a biotech powerhouse. 📍Market size is expected to substantially soar, driven by a surge in clinical trials and strategic collaborations. 📍By 2029, the market will witness significant expansion, solidifying its status as a premier hub for cutting-edge therapies and investment opportunities. ✍️Stay tuned for more updates and insights ✍️ #️⃣ #singleusesupport #PioneeringBiopharma #singleuse #singleusebags #advancedtherapies #mabs #biopharma #bioprocessing #biopharmaceuticals #bioprocess #bioproduction #vaccines #genetherapy #mrna #mrnavaccines #celltherapy #cellandgenetherapy #celltherapymanufacturing #celltherapies #biosimilars #cancertherapy #aav #viralvectors #clinicaltrials #cmo #cdmo #pDNA #pharmaexhibition #pharmaexpoindia #cphipmecindia2023 #pharmaevents #pharma #pharmapackaging #patientcentricpackaging #medicaldrugspackaging #pharmacology #pharmtech #pharmaceuticals #pharmanex #indiaexpomart #CPHIIndia #PMECIndia #PharmaEvent #PharmaIndustry #Science #Inventions #PMEC #Noida #BiggestPharmaEvent #India #Delhi #Event #Healthcare #Health #Exhibition #bioprocess #biopharmaexhibition #bioprocessequipment #singleusebags #2Dbags #3Dbags #upstream #downstream #krubakaranctb

📰📰 As you have seen this week, 2024 looks to be an amazing year for our industry. Here at Nucleus Biologics, we also have some big plans! Navigate over to our NEWS section to stay up to date on the latest, including our recent collaboration agreement with Core Biogenesis. Our blog section also contains interesting industry insights and in-depth analysis of cell culture products and processes, new product releases, and more. #biotech #lifescience #cellculture https://hubs.ly/Q02gHqfj0

Exciting update! Venkat Nelabhotla, the CEO at Vyome Therapeutics, Inc., is going to be a keynote speaker at our 7th Annual Drug Discovery Summit, Princeton,NJ. Grab your spot now by reaching out to- Sid@alcor-wealth.com. Be a part of this awesome summit where we dive deep into the world of drug discovery. #ADDP #DrugDiscovery #Innovation #Summit2024 #biotechnology Secure your spot and let's make this summit a blast! 🚀

Dr. Terri Gaskell, CTO of Rinri Therapeutics, shares her insights on developing and manufacturing a PSC therapeutic at IMAPAC Biomanufacturing 5.0 conference today in London. Her advice? Begin with the end in mind. Don't just focus on what is acceptable in a First-In-Human (FIH) trial, but consider what will likely change to generate a commercial product. Dr. Gaskell emphasizes the importance of collecting everything while developing your manufacturing process. This will facilitate retrospective analysis and help you identify areas for improvement. Additionally, it's crucial to know the sensitivity, robustness, and limitations of your tools. Rely on them only as much as justified. Bank sufficient material to validate your assays if justified in risk assessment. Remember, developing a successful commercial product requires thoughtful planning and attention to detail. Thank you, Terri, for sharing your valuable insights. #productdevelopment #manufacturingprocess #commercialproduct #biotech #advancedtherapies #PSC

HELIX BIOSTRUCTURES: Drug Discovery Services Company of the Year, 2024! "Recognized as a thought leader in the industry, Helix BioStructures is a leading contract research organization (CRO) that specializes in early-stage drug discovery. At the heart of Helix’s expertise lies structure-based drug design—a sophisticated technique that leverages high-resolution, three-dimensional structures of recombinant proteins to drive the development of innovative drug molecules." Read more here: https://loom.ly/4xiUXLE

Check out our article about overcoming the development challenges of PEGylated therapeutics 👇🏻

Alberto Loche and I had the great honor to convene the McKinsey CGT expert panel at the #jpm2024 conference with Lynelle Hoch (BMS), Jak Knowles (Affini-T Therapeutics), Fabian Gerlinghaus (Cellares), Peter Olagunju (March Biosciences), and Cindy Perettie (Kite, A Gilead Company). Thanks all for such an insightful discussion and stay tuned for more insights coming out soon! #biotech #CGT #innovation #mckinseyinsights

Discover the transformative journey of METiS Therapeutics with Techspert! By leveraging Techspert's cutting-edge solutions, METiS has significantly streamlined its drug discovery process, achieving: ⌛ A 70% reduction in research admin time 🚀 50%+ of expert profiles delivered within 24 hours ✅ An 80% acceptance rate for expert profiles With expert insights, METiS made strategic pivots, saving millions in development costs 💰 Ready to enhance your research efficiency and drive innovation? Read the complete case study to see the results we could bring to you: https://lnkd.in/e7gQkzgb

As a CMC leader also supporting marketing at WuXi XDC, I’d like to share this news again which was posted by WuXi XDC’s own new LinkedIn account. WuXi XDC is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. WuXi XDC and Multitude Therapeutics, a clinical stage biotechnology company renowned for ADC platform technologies, have reached a comprehensive partnership in drug-linker technology, which is co-developed with HySlink Therapeutics (“HySlink”), and CRDMO services spanning from discovery to commercialization. I’d like to take this opportunity to invite you to follow WuXi XDC’s LinkedIn account right NOW. #adc #adcs #antibodydrugconjugates #cdmo #crdmo #collaborations #partnership #partnerships